110 related articles for article (PubMed ID: 899883)
1. Intermittent melphalan and prednisolone therapy in plasma cell myeloma.
Mellstedt H; Björkholm M; Holm G
Acta Med Scand; 1977; 202(1-2):5-9. PubMed ID: 899883
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG).
Keldsen N; Bjerrum OW; Dahl IM; Drivsholm A; Ellegaard J; Gadeberg O; Gimsing P; Grønvold T; Hansen MM; Hippe E
Eur J Haematol; 1993 Aug; 51(2):80-5. PubMed ID: 8370422
[TBL] [Abstract][Full Text] [Related]
3. Combined chemotherapy versus melphalan and prednisolone for treatment of myelomatosis.
Gregory WM; Richards MA; Malpas JS
Lancet; 1992 May; 339(8805):1353-4. PubMed ID: 1350010
[No Abstract] [Full Text] [Related]
4. Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.
Taha IA; Ahmad RA; Gray H; Roberts CI; Rogers HJ
Cancer Chemother Pharmacol; 1982; 9(1):57-60. PubMed ID: 7139852
[TBL] [Abstract][Full Text] [Related]
5. Survival in multiple myeloma in Kerala.
Nair MK; Varghese C; Krishnan E; Sankaranarayanan R; Nair B
Natl Med J India; 1993; 6(1):7-10. PubMed ID: 8453369
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
Steinke B; Busch FW; Stapelfeld S; Ostendorf P; Waller HD
Dtsch Med Wochenschr; 1984 Jun; 109(26):1015-9. PubMed ID: 6547386
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma with coexistent myelofibrosis: improvement of myelofibrosis following recovery from multiple myeloma after treatment with melphalan and prednisolone.
Kawauchi K; Mori H; Sugiyama H; Oshimi K; Hirayama A
Jpn J Med; 1991; 30(5):483-6. PubMed ID: 1803051
[TBL] [Abstract][Full Text] [Related]
8. Amyloid myopathy and myeloma: response to treatment.
Sheehan-Dare RA; Simmons AV
Postgrad Med J; 1987 Feb; 63(736):141-2. PubMed ID: 3671242
[TBL] [Abstract][Full Text] [Related]
9. Melphalan plus prednisolone in the treatment of multiple myeloma.
Begum M; Akther A; Khan KH; Kaiser MS; Rahman MJ; Alam MN
Mymensingh Med J; 2012 Jan; 21(1):93-7. PubMed ID: 22314461
[TBL] [Abstract][Full Text] [Related]
10. Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
Mizuno H; Yamao H; Nagura E; Shimizu K; Kamiya O; Takeyama H; Nitta M; Wakita A; Ichikawa A; Kobayashi M; Kawashima K; Saito H;
Intern Med; 2002 Apr; 41(4):290-4. PubMed ID: 11993789
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of multiple myeloma. High-dose intermittent administration of cyclophosphamide and prednisolone--follow up study of 10 years period].
Mizuno H; Ninomiya N; Ohta H; Tokoro K; Yasuma A; Ohnishi K; Ikeda Y
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2286-91. PubMed ID: 6639091
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma treated with high dose intravenous melphalan.
Selby PJ; McElwain TJ; Nandi AC; Perren TJ; Powles RL; Tillyer CR; Osborne RJ; Slevin ML; Malpas JS
Br J Haematol; 1987 May; 66(1):55-62. PubMed ID: 3593657
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group.
Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J
Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904
[TBL] [Abstract][Full Text] [Related]
14. VAD followed by VMCP: an alternative regimen for multiple myeloma.
Wadhwa J; Kumar L; Kochupillai V
Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477
[TBL] [Abstract][Full Text] [Related]
15. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
[TBL] [Abstract][Full Text] [Related]
16. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study.
Oivanen TM; Kellokumpu-Lehtinen P; Koivisto AM; Koivunen E; Palva I
Eur J Haematol; 1999 Feb; 62(2):109-16. PubMed ID: 10052714
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
18. Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma.
Lokhorst HM; Sonneveld P; Wijermans PW; van Marwijk Kooy M; Meuwissen OJ; van Oers RH; van der Griend R; Dekker AW
Br J Haematol; 1996 Jan; 92(1):44-8. PubMed ID: 8562409
[TBL] [Abstract][Full Text] [Related]
19. [Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)].
Ogiya D; Shibayama H; Nakatani E; Ando K; Suzuki K; Kuroda Y; Uchida T; Maruyama D; Matsumoto M; Matsue K; Iida S; Terui Y; Ri M; Chou T; Aotsuka N; Tabata S; Konishi J; Ohashi K; Shinagawa A; Sugiura I; Kuroda J; Miyamoto T; Ogura M; Tobinai K; Kanakura Y; Hotta T
Rinsho Ketsueki; 2016; 57(11):2311-2318. PubMed ID: 27941278
[TBL] [Abstract][Full Text] [Related]
20. Progress in the treatment of multiple myeloma.
Kumar S
Lancet; 2006 Mar; 367(9513):791-2. PubMed ID: 16530557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
